Research Analysts Set Expectations for PRCT FY2025 Earnings

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) – Research analysts at William Blair decreased their FY2025 earnings per share estimates for PROCEPT BioRobotics in a note issued to investors on Wednesday, November 5th. William Blair analyst B. Vazquez now expects that the company will earn ($1.51) per share for the year, down from their previous estimate of ($1.49). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q4 2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($1.01) EPS.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.56%. The business had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. During the same quarter last year, the firm posted ($0.40) EPS. The business’s revenue was up 42.6% compared to the same quarter last year. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS.

A number of other equities research analysts also recently issued reports on PRCT. Truist Financial reduced their price target on shares of PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Leerink Partners reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday. Wells Fargo & Company reduced their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a report on Wednesday. Morgan Stanley decreased their target price on PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 15th. Finally, Wall Street Zen upgraded PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics has an average rating of “Moderate Buy” and a consensus price target of $63.30.

PROCEPT BioRobotics Stock Down 1.0%

PRCT stock opened at $31.30 on Friday. The company has a current ratio of 9.21, a quick ratio of 7.86 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average price is $36.19 and its 200 day moving average price is $47.81. PROCEPT BioRobotics has a 52 week low of $30.80 and a 52 week high of $103.81. The company has a market cap of $1.74 billion, a P/E ratio of -20.46 and a beta of 0.98.

Institutional Investors Weigh In On PROCEPT BioRobotics

Large investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas increased its position in PROCEPT BioRobotics by 16.1% during the first quarter. Teacher Retirement System of Texas now owns 11,080 shares of the company’s stock worth $646,000 after buying an additional 1,537 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of PROCEPT BioRobotics by 32.5% during the first quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $64,000 after acquiring an additional 270 shares during the last quarter. Alps Advisors Inc. increased its position in PROCEPT BioRobotics by 41.6% during the 1st quarter. Alps Advisors Inc. now owns 14,828 shares of the company’s stock worth $864,000 after purchasing an additional 4,353 shares in the last quarter. Arizona State Retirement System increased its position in PROCEPT BioRobotics by 3.2% during the 1st quarter. Arizona State Retirement System now owns 14,737 shares of the company’s stock worth $859,000 after purchasing an additional 452 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in PROCEPT BioRobotics by 8.6% in the 1st quarter. New York State Common Retirement Fund now owns 205,495 shares of the company’s stock valued at $11,972,000 after purchasing an additional 16,341 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).